Technical Data
E3372-01G
EPHB3 (Ephrin Type-B receptor 3, Tyrosine-protein Kinase Receptor HEK-2, EPH-like Kinase 2, EK2, Tyrosine-protein Kinase TYRO6, ETK2, HEK2, TYRO6)
Description:
EphB3, is a 110-130kD member of the transmembrane Eph receptor tyrosine kinase family. The A and B classes of Eph proteins are distinguished by Ephrin ligand binding preference but have a common structural organization. Eph-Ephrin interactions are widely involved in the regulation of cell migration, tissue morphogenesis, and cancer progression (1). The 526aa extracellular domain (ECD) of mature human EphB3 contains a ligand binding domain followed by a cysteine rich region and two fibronectin type III domains. The 418aa cytoplasmic domain contains a tyrosine kinase domain, a sterile alpha motif (SAM), and a PDZ binding motif (2). Within the ECD, human EphB3 shares 96aa sequence identity with mouse and rat EphB3. Binding of EphB3 to its ligands Ephrin-B1, B2, and B3 triggers forward signaling through EphB3 as well as reverse signaling through the Ephrin (1, 3). EphB3 also interacts in cis with the receptor tyrosine kinase Ryk (4). Activation of its kinase is required for some but not all of the effects of EphB3 on cellular adhesion, motility, and morphology (5). EphB3 is widely expressed during development and in the adult; it shows a complementary tissue distribution to the Ephrin-B ligands (6-9). EphB3 function is important in vascular, nervous system, thymocyte, and palate development (6, 7, 10-12). It directs embyronic neuronal axon pathfinding, and its upregulation on local macrophages following neuronal injury promotes the growth of regenerating axons (10, 13). EphB3 inhibits colorectal carcinogenesis and invasion by preventing the migration of tumor cells out of the intestinal crypt (9, 14). EphB3 function is supported by the cooperative action of EphB2 in several of these processes (6, 10-12, 15).

Applications:
Suitable for use in Western Blot. Other applications not tested.

Recommended Dilution:
Western Blot: 1ug/ml
Optimal dilutions to be determined by the researcher.

Storage and Stability:
Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute with sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -20C. Reconstituted product is stable for 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
TypeIsotypeCloneGrade
PabIgGAffinity Purified
SizeStorageShippingSourceHost
100ug-20CBlue IceHumanSheep
Concentration:
Not determined
Immunogen:
Recombinant corresponding to aa38-550 from human EphB3 expressed in NSO cells (P54753).
Purity:
Purified by immunoaffinity chromatography.
Form
Supplied as a lyophilized powder in PBS, trehalose. Reconstitute with sterile PBS to 200ug/ml.
Specificity:
Recognizes human EphB3. Species sequence homology: Recombinant mouse EphB3, recombinant rat EphB1 (1%), recombinant human EphB2 and rhEphB4 (3%).
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Pasquale, E.B. (2008) Cell 133:38. 2. Bohme, B. et al. (1993) Oncogene 8:2857. 3. Pasquale, E.B (2004) Nat. Neurosci. 7:417. 4. Trivier, E. and T.S. Ganesan (2002) J. Biol. Chem. 277:23037. 5. Miao, H. et al. (2005) J. Biol. Chem. 280:923. 6. Adams, R.H. et al. (1999) Genes Dev. 13:295. 7. Krull, C.E. et al. (1997) Curr. Biol. 7:571. 8.Willson, C.A. et al. (2006) J. Mol. Histol. 37:369. 9. Cortina, C. et al. (2007) Nature Genet. 39:1376. 10.Birgbauer, E. et al. (2000) Development 127:1231. 11. Alfaro, D. et al. (2008) Immunology 125:131. 12. Risley, M. et al. (2009) Mech. Dev. 126:230. 13. Liu, X. et al. (2006) J. Neurosci. 26:3087. 14. Batlle, E. et al. (2005) Nature 435:1126. 15. Holmberg, J. et al. (2006) Cell 125:1151.